NASDAQ:SWAV

ShockWave Medical Stock Forecast, Price & News

$174.68
+1.27 (+0.73 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$168.53
$174.98
50-Day Range
$157.48
$201.49
52-Week Range
$45.29
$203.74
Volume137,157 shs
Average Volume328,967 shs
Market Capitalization$6.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.28
30 days | 90 days | 365 days | Advanced Chart
Receive SWAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ShockWave Medical and its competitors with MarketBeat's FREE daily newsletter.


ShockWave Medical logo

About ShockWave Medical

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

485th out of 2,215 stocks

Surgical & Medical Instruments Industry

43rd out of 181 stocks

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ShockWave Medical (NASDAQ:SWAV) Frequently Asked Questions

Is ShockWave Medical a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ShockWave Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SWAV, but not buy additional shares or sell existing shares.
View analyst ratings for ShockWave Medical
or view top-rated stocks.

What stocks does MarketBeat like better than ShockWave Medical?

Wall Street analysts have given ShockWave Medical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ShockWave Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ShockWave Medical's next earnings date?

ShockWave Medical is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for ShockWave Medical
.

How can I listen to ShockWave Medical's earnings call?

ShockWave Medical will be holding an earnings conference call on Monday, August 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were ShockWave Medical's earnings last quarter?

ShockWave Medical, Inc. (NASDAQ:SWAV) posted its quarterly earnings data on Monday, May, 10th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.26. The business earned $31.90 million during the quarter, compared to analyst estimates of $31.33 million. ShockWave Medical had a negative net margin of 83.47% and a negative trailing twelve-month return on equity of 30.92%. The business's quarterly revenue was up 109.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.59) EPS.
View ShockWave Medical's earnings history
.

How has ShockWave Medical's stock been impacted by COVID-19?

ShockWave Medical's stock was trading at $34.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SWAV shares have increased by 407.2% and is now trading at $174.68.
View which stocks have been most impacted by COVID-19
.

What guidance has ShockWave Medical issued on next quarter's earnings?

ShockWave Medical issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $195 million-205 million, compared to the consensus revenue estimate of $158.99 million.

What price target have analysts set for SWAV?

7 Wall Street analysts have issued twelve-month price objectives for ShockWave Medical's shares. Their forecasts range from $152.00 to $208.00. On average, they expect ShockWave Medical's share price to reach $193.00 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price.
View analysts' price targets for ShockWave Medical
or view top-rated stocks among Wall Street analysts.

Who are ShockWave Medical's key executives?

ShockWave Medical's management team includes the following people:
  • Mr. Douglas E. Godshall, Pres, CEO & Director (Age 56, Pay $972.39k)
  • Mr. Daniel Puckett, CFO & Sec. (Age 57, Pay $568.34k)
  • Mr. Isaac Zacharias, Chief Commercial Officer (Age 46, Pay $571.37k)
  • Mr. Daniel Hawkins, Founder and Sr. Advisor (Age 54)
  • Mr. John M. Adams, Co-Founder and Technical Advisor (Age 74)
  • Mr. Mike Maszy, VP of Operations
  • Ms. Debbie Kaster, VP of Investor Relations
  • Mr. Hajime Tada J.D., Gen. Counsel & Sec.
  • Mr. Rob Williamson Jr., VP of Sales
  • Mr. Robert Fletcher, VP of Marketing

What is Doug Godshall's approval rating as ShockWave Medical's CEO?

8 employees have rated ShockWave Medical CEO Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among ShockWave Medical's employees.

Who are some of ShockWave Medical's key competitors?

What other stocks do shareholders of ShockWave Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), The Walt Disney (DIS), Square (SQ), The Trade Desk (TTD), salesforce.com (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

When did ShockWave Medical IPO?

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ShockWave Medical's stock symbol?

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Who are ShockWave Medical's major shareholders?

ShockWave Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fulton Bank N.A. (0.00%). Company insiders that own ShockWave Medical stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frederic H Moll, Isaac Zacharias, Kurt F Gallo, Laura Francis and Sofinnova Capital Vii Fcpr.
View institutional ownership trends for ShockWave Medical
.

Which institutional investors are buying ShockWave Medical stock?

SWAV stock was acquired by a variety of institutional investors in the last quarter, including Fulton Bank N.A..
View insider buying and selling activity for ShockWave Medical
or or view top insider-buying stocks.

How do I buy shares of ShockWave Medical?

Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ShockWave Medical's stock price today?

One share of SWAV stock can currently be purchased for approximately $174.68.

How much money does ShockWave Medical make?

ShockWave Medical has a market capitalization of $6.11 billion and generates $67.79 million in revenue each year. The company earns $-65,700,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does ShockWave Medical have?

ShockWave Medical employs 449 workers across the globe.

What is ShockWave Medical's official website?

The official website for ShockWave Medical is www.shockwavemedical.com.

Where are ShockWave Medical's headquarters?

ShockWave Medical is headquartered at 5403 Betsy Ross Drive, Santa Clara CA, 95054.

How can I contact ShockWave Medical?

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected]


This page was last updated on 7/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.